Interview with Carlos Gallardo, General Manager UK & Ireland, Almirall UK
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Address: 1 The Square
Stockley Park
Uxbridge
Middlesex
UB11 1TD
Tel: +44 (0) 20 7160 2500
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. Almirall researches, developes, produces and markets proprietary R&D medicines and those under licence with the aim of improving people’s health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of:
x Asthma,
x COPD (Chronic Obstructive Pulmonary Disease),
x Rheumatoid arthritis,
x Multiple sclerosis,
x Psoriasis,
x Dermatology
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
